Pretty Sara Idiculla1, Dhineshreddy Gurala2, Manikandan Palanisamy3, Rajendran Vijayakumar3, Sindhu Dhandapani4, Elanagan Nagarajan5. 1. University of Missouri Health Care, Columbia, Missouri, USA, sarahidiculla.psi@gmail.com. 2. Staten Island University Hospital, Northwell Health, Staten Island, New York, USA. 3. Majmaah University, Industrial Area, Al Majma'ah, Saudi Arabia. 4. Cure Hospital, Vellakovil, India. 5. Columbia University Medical Center, New York, New York, USA.
Abstract
BACKGROUND: Cerebral sinus venous thrombosis (CSVT) is a relatively rare, potentially fatal neurological condition that can be frequently overlooked due to the vague nature of its clinical and radiological presentation. A literature search on PubMed using the keyword "Cerebral sinus venous thrombosis" was performed. We searched for the epidemiology, risk factors, pathophysiology, clinical features, diagnosis, and treatment of CSVT. All full-text articles in the last 10 years, in adults (>18 years), and the English language were included. We aim to give a comprehensive review of CSVT, with a primary focus on the management of the disease. SUMMARY: The literature search revealed 404 articles that met our criteria. CSVT is a relatively rare condition that accounts for approximately 1% of all forms of stroke. They can be subdivided into acute, subacute, and chronic forms based on the time of onset of clinical symptoms. It is a multifactorial disease, and the major forms of clinical presentation include isolated intracranial hypertension syndrome, focal neurological deficits, and cavernous sinus syndrome. MRI with magnetic resonance venogram (MRV) is considered the gold standard for diagnosis. Anticoagulation with heparin or low-molecular-weight heparin is the mainstay of treatment. Endovascular management is indicated for those cases with severe symptoms or worsening of symptoms despite anticoagulation therapy. Favorable outcomes have been reported in patients who receive early diagnosis and treatment. CONCLUSION: CSVT is a potentially fatal neurological condition that is often under-diagnosed due to its nonspecific presentation. Timely diagnosis and treatment can reduce morbidity and mortality, remarkably improving the outcome in affected individuals.
BACKGROUND:Cerebral sinus venous thrombosis (CSVT) is a relatively rare, potentially fatal neurological condition that can be frequently overlooked due to the vague nature of its clinical and radiological presentation. A literature search on PubMed using the keyword "Cerebral sinus venous thrombosis" was performed. We searched for the epidemiology, risk factors, pathophysiology, clinical features, diagnosis, and treatment of CSVT. All full-text articles in the last 10 years, in adults (>18 years), and the English language were included. We aim to give a comprehensive review of CSVT, with a primary focus on the management of the disease. SUMMARY: The literature search revealed 404 articles that met our criteria. CSVT is a relatively rare condition that accounts for approximately 1% of all forms of stroke. They can be subdivided into acute, subacute, and chronic forms based on the time of onset of clinical symptoms. It is a multifactorial disease, and the major forms of clinical presentation include isolated intracranial hypertension syndrome, focal neurological deficits, and cavernous sinus syndrome. MRI with magnetic resonance venogram (MRV) is considered the gold standard for diagnosis. Anticoagulation with heparin or low-molecular-weight heparin is the mainstay of treatment. Endovascular management is indicated for those cases with severe symptoms or worsening of symptoms despite anticoagulation therapy. Favorable outcomes have been reported in patients who receive early diagnosis and treatment. CONCLUSION: CSVT is a potentially fatal neurological condition that is often under-diagnosed due to its nonspecific presentation. Timely diagnosis and treatment can reduce morbidity and mortality, remarkably improving the outcome in affected individuals.
Authors: Isaac See; John R Su; Allison Lale; Emily Jane Woo; Alice Y Guh; Tom T Shimabukuro; Michael B Streiff; Agam K Rao; Allison P Wheeler; Suzanne F Beavers; Anna P Durbin; Kathryn Edwards; Elaine Miller; Theresa A Harrington; Adamma Mba-Jonas; Narayan Nair; Duong T Nguyen; Kawsar R Talaat; Victor C Urrutia; Shannon C Walker; C Buddy Creech; Thomas A Clark; Frank DeStefano; Karen R Broder Journal: JAMA Date: 2021-06-22 Impact factor: 56.272
Authors: Sara E Oliver; Megan Wallace; Isaac See; Sarah Mbaeyi; Monica Godfrey; Stephen C Hadler; Tara C Jatlaoui; Evelyn Twentyman; Michelle M Hughes; Agam K Rao; Anthony Fiore; John R Su; Karen R Broder; Tom Shimabukuro; Allison Lale; David K Shay; Lauri E Markowitz; Melinda Wharton; Beth P Bell; Oliver Brooks; Veronica McNally; Grace M Lee; H Keipp Talbot; Matthew F Daley Journal: MMWR Morb Mortal Wkly Rep Date: 2022-01-21 Impact factor: 17.586